

Claims

1 A method of treating wounds in a patient which comprises treating the patient with an effective amount of a cGMP PDE5 inhibitor, or a
 5 pharmaceutical composition thereof, wherein the wound type is selected from: chronic venous ulcers, chronic arterial ulcers, chronic decubitus and acute wounds.

2 The use of a cGMP PDE5 inhibitor for the manufacture of a medicament
 10 for the treatment of wounds, selected from the following types: chronic venous ulcers, chronic arterial ulcers, chronic decubitus and acute wounds.

15 Sub A31 3 A method or use as claimed in claim 1 or 2, wherein the inhibitor is administered orally or topically.

4 A method or use as claimed in any preceding claim, wherein the wherein the inhibitor has an IC50 at less than 100 nanomolar.

20 5 A method or use as claimed in claim 4, wherein the inhibitor has a selectivity ratio in excess of 1000.

25 Sub A31 6 A method or use as claimed in any preceding claim, wherein the inhibitor is sildenafil.

7 A method or use as claimed in claim 6, wherein the daily dosage is 5 to 500 mg.

8 A method or use as claimed in claim 7, wherein the daily dosage is 10 to
 30 100 mg.

09927344-081001

SYN
ALL

5

The use of a cGMP PDE5 inhibitor in combination with a matrix metalloprotease inhibitor (MMP), and/or a urokinase type plasminogen activator inhibitor (uPA), for the manufacture of a medicament for the treatment of wounds, selected from the following types: chronic venous ulcers, chronic arterial ulcers, chronic decubitus and acute wounds.

10

Use as claimed in claim 9, wherein the MMP is selected from the group comprising: inhibitors of MMP-3, MMP-12 and MMP-13.

10

11

A pharmaceutical pack comprising: a pharmaceutical composition comprising a PDE5 inhibitor, directions relating to the use of the composition for treating wounds, and a container.

15

12

A combination of a PDE5 inhibitor together with a matrix metalloprotease inhibitor (MMP) and/or a urokinase type plasminogen activator inhibitor (uPA).

13

A combination as claimed in claim 12, wherein the MMP is selected from the group comprising: inhibitors of MMP-3, MMP-12 and MMP-13.

20

0997344 031001
"HEZ2660"